The Most Versatile Therapeutic Platform in Medicine
We have built a living-medicine platform that turns safe, well-characterized microorganisms into programmable therapeutic agents — capable of preventing and treating disease across every major disease category, delivered orally, manufactured at commodity scale.
Regional precision medicine, built into the strain.
Disease doesn’t look the same in Nairobi as it does in Boston. GEOSTRAIN is the first platform that adapts living medicines to local pathogen variants, HLA prevalence, and pharmacogenomic profiles — one chassis, configured per region.
- Pathogen-aware design — codon-optimized for the dominant strain in your region (e.g., P. falciparum kelch13 C580Y in the Mekong; HER2-amplified breast cancer with TP53 co-mutation in Sub-Saharan Africa).
- HLA-matched epitopes — antigens chosen to bind the HLA alleles common in the target population, not just the European reference set.
- Pharmacogenomic dosing — CYP2D6, CYP2C19, NAT2 distributions inform dose; same drug, regional regimen.
- Cold-chain-free delivery — oral, room-temperature stable, distributable through existing health infrastructure tiers.
🎈 HER2-SSA — identifies TP53 co-mutation pattern in Sub-Saharan cohorts; recommends adjusted dosing & biomarker stratification.
🧒 TB-Pediatric — combines pediatric pharmacogenomics with local M. tuberculosis resistance patterns from WHO/GISAID.
Living Medicines, Engineered at the DNA Level
Our platform begins with safe, well-characterized microorganisms that have decades of documented human use — probiotic yeast, beneficial bacteria, organisms already present in the human body. We engineer these organisms at the genetic level to become precision therapeutic agents:
1. Antigen Surface Display
Therapeutic proteins are displayed at extremely high density on the organism's cell surface — tens of thousands of molecules per cell — ensuring potent immune activation upon contact with the body's immune system.
2. Gut Immune Activation
Delivered orally, the engineered organisms interact directly with the gut-associated lymphoid tissue (GALT) — the body's largest immune organ. This activates both cellular immunity (killer T cells that hunt disease) and mucosal immunity (antibodies at body surfaces) from a single dose.
3. Intrinsic Adjuvant Activity
The organism's own cell wall components activate innate immune receptors on dendritic cells, providing built-in immune stimulation without requiring any external adjuvant — a critical simplification for global deployment.
4. Multi-Layered Biocontainment
Every organism contains engineered safety systems that prevent survival outside the human body. Multiple independent kill mechanisms ensure escape frequencies below one in ten billion per generation — rigorously validated.
Why a Living-Medicine Platform Changes Everything
Traditional drug development builds one molecule for one disease at a cost of $2–3 billion and a decade of development time. Our platform is fundamentally different:
🔄 Programmable
The same organism chassis can be engineered with different therapeutic payloads for entirely different diseases. A yeast engineered for cancer immunotherapy uses the same core architecture as one engineered for infectious disease prevention.
🎯 Multi-Target
A single organism can display multiple therapeutic molecules simultaneously — targeting several disease antigens at once. This multi-target approach prevents immune escape (the primary failure mode of existing immunotherapies) and enables our regional multi-disease strategy.
📊 Exponentially Scalable
New therapeutic programs require only the design of a new payload — the chassis, manufacturing process, safety systems, and delivery form remain the same. Each new program is faster and cheaper than the last.
🌍 Built for Global Access
Oral delivery. Room temperature stability. Commodity-scale fermentation. No cold chain. No IV infrastructure. Under $1 per dose. Every design decision optimizes for reaching 8 billion people.
Four Organisms. Infinite Therapeutic Possibilities.
We do not depend on a single organism. Our platform spans multiple chassis microbes, each selected for specific therapeutic advantages — ensuring that every disease can be matched with the optimal delivery system.
Probiotic Yeast
GRAS-status probiotic with decades of human safety data. Exceptional for high-density surface display of antigens and oral delivery to gut immune tissue.
Probiotic Bacteria
Well-characterized beneficial bacteria with natural gut colonization. Ideal for sustained therapeutic protein secretion and microbiome integration.
Food-Grade Bacteria
Organisms with extensive history in food production. Optimized for mucosal immune activation and antigen delivery at intestinal surfaces.
Gut Commensal Bacteria
Native inhabitants of the human gut. Engineered for deep microbiome integration and long-duration therapeutic payload delivery.
Artificial Intelligence Accelerating Every Stage
Our AI engine does not assist drug discovery. It drives it. Autonomous AI systems continuously scan, analyze, design, and optimize — compressing years of traditional R&D into days.
🔍 Target Discovery
AI scans millions of genomic records, protein structures, and clinical databases to identify novel therapeutic targets invisible to traditional research.
🧬 Construct Design
AI generates thousands of optimized DNA constructs, selecting the ideal sequence, codon optimization, and display architecture for maximum therapeutic effect.
🔬 Binding & Efficacy Prediction
Molecular dynamics simulations predict binding affinity, immune activation potential, and in vivo efficacy before a single experiment is run.
🛡️ Safety Screening
AI screens every candidate against thousands of off-target proteins, predicting toxicity and immunogenicity risks before they reach the laboratory.
📚 Literature Intelligence
AI continuously ingests the global biomedical literature, extracting findings, identifying competitive threats, and discovering cross-portfolio opportunities.
🏛️ Regulatory Intelligence
AI analyzes thousands of FDA precedents to predict approval pathways and auto-generates complete, submission-ready regulatory packages.
Rethinking How Medicine Is Practiced
Regional Multi-Cancer Strategy
Instead of developing one drug for one cancer, we engineer single organisms that target all cancers in a body region. One oral therapeutic for all cancers of the lower GI tract. One for all breast and chest wall cancers. One for all head and neck cancers. This regional approach dramatically simplifies treatment, reduces cost, and makes cancer immunotherapy practical in settings where individual cancer diagnosis is impossible.
Multi-antigen display prevents immune escape — the leading cause of failure in current single-target cancer immunotherapies.
Syndromic Multi-Pathogen Strategy
In the developing world, patients present with clinical syndromes — "undifferentiated fever," "bloody diarrhea," "respiratory distress" — not specific diagnoses, because diagnostic laboratories don't exist. We engineer organisms that target all major pathogens causing a given syndrome. Treat the syndrome, not the diagnosis. No testing required.
This approach eliminates the diagnostic bottleneck that kills millions annually in resource-limited settings.
Active Programs Across Seven Disease Categories
Our platform is not theoretical. We have active therapeutic programs with validated targets, designed constructs, and defined regulatory pathways.
Oncology
Multi-antigen oral cancer immunotherapy across every major body region. Regional multi-cancer strategy targeting all cancers of the brain, thorax, GI tract, breast, urogenital, gynecologic, skin, blood, and endocrine systems.
Multiple Active ProgramsInfectious Disease
Syndromic multi-pathogen oral immunotherapy. Active programs for undifferentiated fever, diarrheal diseases, respiratory infections, and sexually transmitted infections — each covering all major causative organisms.
Multiple Active ProgramsAutoimmune & Inflammatory
Mucosal immune modulation for autoimmune conditions. Engineered tolerance induction via gut immune tissue — addressing root cause rather than systemic immunosuppression.
Active ResearchGenetic & Rare Diseases
Oral enzyme and protein replacement via engineered microbial biofactories. Our commodity-scale manufacturing makes rare disease therapeutics economically viable for the first time.
Active ResearchNext-Generation Vaccines
Oral, ambient-stable, multi-antigen immunization platforms. No cold chain, no needles, no trained healthcare workers required. Designed for deployment in the most resource-limited settings on Earth.
Active ResearchMicrobiome Therapeutics
Deep microbiome integration for sustained therapeutic delivery. Engineered gut commensals for metabolic, neurological, and inflammatory disease modification.
In Development